Flupenthixol

Table of contents

  • Brand Names
  • Drug Combinations
  • Chemistry
  • Pharmacologic Category
  • Mechanism of Action
  • Therapeutic Use
  • Contraindications
  • Warnings and Precautions
  • Adverse Reactions
  • Caution and personalized dose adjustment in patients with the following genotypes
  • Other genes that may be involved
  • Drug Interactions
  • Dosage
  • Pharmacokinetics and Pharmacodynamics
  • Special Considerations

Brand Names

Europe

Austria: Fluanxol; Belgium: Fluanxol; Bulgaria: Fluanxol; Czech Republic: Fluanxol; Denmark: Fluanxol; Estonia: Fluanxol; Finland: Fluanxol; France: Fluanxol; Germany: Fluanxol, Flupendura, Flupentixol; Hungary: Fluanxol; Ireland: Depixol, Fluanxol; Latvia: Fluanxol; Malta: Depixol, Fluanxol; Netherlands: Fluanxol; Poland: Fluanxol; Portugal: Fluanxol; Romania: Fluanxol; Slovakia: Fluanxol; Slovenia: Fluanxol; Sweden: Fluanxol; UK: Depixol.

North America

Canada: Fluanxol.

Latin America

Mexico: Fluanxol.

Drug combinations

Flupenthixol and Melitracene

Chemistry

Flupenthixol: C~23~H~25~F~3~N~2~OS. Mw: 434.52. cis-2-[4-[3-[2-(trifluoromethyl)thioxanthen-9-ylidene]propyl]piperazin-1-yl]ethanol. CAS-2709-56-0.

Pharmacologic Category

Antipsychotics; Thioxanthenes. Typical Antipsychotic Agent. (ATC-Code: N05AF01).

Mechanism of action

Flupenthixol is a thioxanthene antipsychotic which blocks postsynaptic dopamine receptors in CNS, resulting in inhibition of dopamine-mediated effects.

Therapeutic use

Belongs to a group of medicines called thioxanthene neuroleptics. Helps to correct chemical imbalances in the brain, which may cause mental illness. Used for long-term treatment of schizophrenia.

Pregnancy and lactiation implications

Unlabeled use

Contraindications

Hypersensitivity to flupenthixol, phenothiazines, thioxanthenes, or any component of the formulation. Acute intoxication (ethanol, barbiturate, or opioid). Blood dyscrasias. Cerebrovascular or renal insufficiency. Coma. Pheochromocytoma. Severe CNS depression. Severely agitated patients. Suspected or established subcortical brain damage. Severe cardiovascular disease/circulatory collapse.

Warnings and precautions

May alter cardiac conduction (avoid use in underlying QT prolongation, in patients taking medicines which prolong the QT interval, or cause polymorphic ventricular tachycardia). May cause anticholinergic effects (use with caution in decreased GI motility, paralytic ileus, urinary retention, BPH, xerostomia, or visual problems). Myelosuppression (e.g. leukopenia, agranulocytosis) observed with antipsychotic use (use contraindicated in bone marrow suppression). Esophageal dysmotility or aspiration are possible (use with caution in risk of pneumonia). May cause extrapyramidal symptoms, including acute dystonic reactions, akathisia, pseudoparkinsonism, and tardive dyskinesia. Neuroleptic malignant syndrome might occur. May cause orthostatic hypotension (use with caution in cerebrovascular disease, cardiovascular disease, hypovolemia, or concurrent medication use which may predispose to hypotension/bradycardia). Pigmentary retinopathy might occur. May cause sedation. Impaired core body temperature regulation might occur (caution with strenuous exercise, heat exposure, dehydration, and concomitant medication possessing anticholinergic effects). Use with caution in severe cardiovascular disease, narrow-angle glaucoma, hepatic impairment, myasthenia gravis (may be exacerbated by cholinergic blockade), Parkinson’s disease (may be more sensitive to adverse effects), breast cancer or other prolactin-dependent tumors (elevates prolactin levels), renal impairment, respiratory disease, or in patients at risk of seizures. Elderly patients with dementia-related psychosis treated with antipsychotics are at increased risk of death. Flupenthixol not approved for this indication. May mask toxicity of other drugs or conditions (e.g. intestinal obstruction, Reye’s syndrome, brain tumor) due to antiemetic effects.

Information

Legal

Legal Notice
Privacy Policy
Cookie Policy

Contact

Phone: +34-981-780505
Email: genomicmedicine@wagem.org
Location: Sta Marta de, C. P. Babío, S/N, 15165 Bergondo, A Coruña

Copyright © 2023 WAGEM

Add to cart